Literature DB >> 2893190

Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.

.   

Abstract

Two regimens of steroid treatment for the initial attack of idiopathic nephrotic syndrome in children were compared in a controlled multicentre study. Short-course prednisone therapy consisted of 60 mg/m2 per 24 h until proteinuria had disappeared for 3 days, followed by 40 mg/m2 per 48 h until complete remission had occurred. The standard prednisone therapy was 60 mg/m2 per 24 h for 4 weeks, followed by 40 mg/m2 per 48 h for 4 weeks. 61 children with a first attack of idiopathic nephrotic syndrome were allocated at random to these groups. Urinary remission in the short-course group was achieved after 14 days of daily prednisone, and complete remission after an additional 16 days of alternate day prednisone. The cumulative rate of patients with sustained remissions after two years was significantly lower after the short course than after standard treatment (19% versus 41%, p = 0.001). The mean duration of remission in patients with a relapse was half as long after the short course (79 versus 169 days, p = 0.004). Complete initial remission of steroid responsive nephrotic syndrome can be obtained with half the standard prednisone dose, but the short course is followed by a higher rate of relapses, that require repeated prednisone administrations. In the long term, the standard regimen is preferable.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2893190

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  56 in total

1.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

Review 2.  Evidence-based management of steroid-sensitive nephrotic syndrome.

Authors:  Elisabeth M Hodson; Jonathan C Craig; Narelle S Willis
Journal:  Pediatr Nephrol       Date:  2005-06-21       Impact factor: 3.714

3.  Dosing of glucocorticosteroids in nephrotic syndrome.

Authors:  Otto Mehls; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2011-09-09       Impact factor: 3.714

4.  Disruption of PTPRO causes childhood-onset nephrotic syndrome.

Authors:  Fatih Ozaltin; Tulin Ibsirlioglu; Ekim Z Taskiran; Dilek Ertoy Baydar; Figen Kaymaz; Mithat Buyukcelik; Beltinge Demircioglu Kilic; Ayse Balat; Paraskevas Iatropoulos; Esin Asan; Nurten A Akarsu; Franz Schaefer; Engin Yilmaz; Ayşin Bakkaloglu
Journal:  Am J Hum Genet       Date:  2011-06-30       Impact factor: 11.025

5.  Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations.

Authors:  Gil Chernin; Virginia Vega-Warner; Dominik S Schoeb; Saskia F Heeringa; Bugsu Ovunc; Pawaree Saisawat; Roxana Cleper; Fatih Ozaltin; Friedhelm Hildebrandt
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

6.  No evidence for genotype/phenotype correlation in NPHS1 and NPHS2 mutations.

Authors:  Michael Schultheiss; Rainer G Ruf; Bettina E Mucha; Roger Wiggins; Arno Fuchshuber; Anne Lichtenberger; Friedhelm Hildebrandt
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

7.  Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors:  J H Ehrich; J Brodehl
Journal:  Eur J Pediatr       Date:  1993-04       Impact factor: 3.183

8.  Complete remission of nephrotic syndrome in an infant with focal segmental glomerulosclerosis: is it renin-angiotensin blockade?

Authors:  Neveen A Soliman; Magdi Francis; Saskia F Heeringa; Gil Chernin
Journal:  Pediatr Nephrol       Date:  2008-10-14       Impact factor: 3.714

Review 9.  Minimal Change Disease.

Authors:  Marina Vivarelli; Laura Massella; Barbara Ruggiero; Francesco Emma
Journal:  Clin J Am Soc Nephrol       Date:  2016-12-09       Impact factor: 8.237

10.  A novel TRPC6 mutation that causes childhood FSGS.

Authors:  Saskia F Heeringa; Clemens C Möller; Jianyang Du; Lixia Yue; Bernward Hinkes; Gil Chernin; Christopher N Vlangos; Peter F Hoyer; Jochen Reiser; Friedhelm Hildebrandt
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.